Forte Biosciences, Inc.
FBRX
$18.31
-$0.78-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.37% | -58.18% | -0.55% | -24.63% | -28.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.04% | -9.67% | 106.61% | 15.20% | -15.53% |
| Operating Income | -113.04% | 9.67% | -106.61% | -15.20% | 15.53% |
| Income Before Tax | -110.70% | 10.09% | -111.00% | -21.85% | 15.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.70% | 10.09% | -111.00% | -21.85% | 15.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.70% | 10.09% | -111.00% | -21.85% | 15.70% |
| EBIT | -113.04% | 9.67% | -106.61% | -15.20% | 15.53% |
| EBITDA | -113.09% | 9.71% | -106.68% | -15.15% | 15.62% |
| EPS Basic | 78.12% | 85.87% | 65.88% | 63.26% | 30.90% |
| Normalized Basic EPS | 78.12% | 85.87% | 65.88% | 63.27% | 30.90% |
| EPS Diluted | 78.12% | 85.87% | 65.88% | 63.26% | 30.90% |
| Normalized Diluted EPS | 78.12% | 85.87% | 65.88% | 63.27% | 30.90% |
| Average Basic Shares Outstanding | 863.08% | 536.47% | 518.40% | 231.69% | 21.99% |
| Average Diluted Shares Outstanding | 863.08% | 536.47% | 518.40% | 231.69% | 21.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |